60 Recruiting Studies Using Sacituzumab Govitecan
Active clinical trials that use this intervention, sourced directly from the NIH registry.
Browse by conditionTrials Using Sacituzumab Govitecan
A Study of the Safety and Efficacy of Various Combinations of Avelumab as Therapy in Locally Advanced or Metastatic Urothelial Carcinoma (JAVELIN Bladder Medley)
📍 Beacon Cancer Care — Coeur d'Alene, Idaho
Locally Advanced or Metastatic Urothelial Carcinoma
View Study & Checklist ➔Combination of Ipi/Nivo Plus Sacituzumab Govitecan in Metastatic Cisplatin Ineligible Urothelial Carcinoma Patients
📍 Moffitt Cancer Center — Tampa, Florida
Metastatic Urothelial Carcinoma
View Study & Checklist ➔Study of IDE397 in Participants With Solid Tumors Harboring MTAP Deletion
📍 Honor Health Research Institute — Scottsdale, Arizona
Solid Tumor
View Study & Checklist ➔Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer
📍 Arizona Oncology Associates, PC-Hope,1845 W Orange Grove Rd — Tucson, Arizona
Triple Negative Breast Cancer
View Study & Checklist ➔Sacituzumab Govitecan in Patients With Metastatic Castration-Resistant Prostate Cancer Progressing on Second Generation AR-Directed Therapy
📍 Memorial Sloan-Kettering Cancer Center — New York, New York
Prostate Cancer
View Study & Checklist ➔A Study of Sacituzumab Govitecan (IMMU-132) in Endometrial Carcinoma
📍 Smilow Cancer Hospital at Yale New Haven — New Haven, Connecticut
Endometrial Carcinoma
View Study & Checklist ➔Sacituzumab Govitecan +/- Pembrolizumab In HR+ / HER2 - MBC
📍 Emory University/Winship Cancer Institute — Atlanta, Georgia
Invasive Breast Cancer
View Study & Checklist ➔Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer
📍 O'Neal Comprehensive Cancer Center — Birmingham, Alabama
Stage III Breast Cancer
View Study & Checklist ➔Study of Sacituzumab Govitecan Combinations in First-line Treatment of Participants With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC)
📍 Alaska Oncology and Hematology, LLC. — Anchorage, Alaska
Non-small Cell Lung Cancer
View Study & Checklist ➔Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer After Platinum-Based Chemotherapy and Immunotherapy (ASCENT-GYN-01/GOG-3104/ENGOT-en26)
📍 University of Arkansas for Medical Sciences — Little Rock, Arkansas
Endometrial Cancer
View Study & Checklist ➔Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy
📍 Ironwood Physicians P.C. dba Ironwood Cancer and Research Centers — Chandler, Arizona
Locally Advanced or Unresectable Metastatic Breast Cancer
View Study & Checklist ➔Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-3475-D46)
📍 Infirmary Cancer Care ( Site 0418) — Mobile, Alabama
Carcinoma, Non-Small-Cell Lung
View Study & Checklist ➔Study of Novel Treatment Combinations in Patients With Lung Cancer
📍 Arizona Oncology Associates,Substudy-02 — Tucson, Arizona
Lung Cancer
View Study & Checklist ➔Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer
📍 Alaska Oncology and Hematology — Anchorage, Alaska
Triple Negative Breast Cancer
View Study & Checklist ➔Study to Evaluate Sacituzumab Govitecan in Combination With Talazoparib in Patients With Metastatic Breast Cancer.
📍 Massachusetts General Hospital Cancer Center — Boston, Massachusetts
Breast Cancer
View Study & Checklist ➔Alpelisib And Sacituzumab Govitecan For Treatment Of Breast Cancer
📍 The University of Kansas Clinical Research Center — Fairway, Kansas
Breast Cancer
View Study & Checklist ➔Study of Sacituzumab Govitecan in Participants With Metastatic Solid Tumors
📍 Alaska Oncology & Hematology, LLC — Anchorage, Alaska
Metastatic Solid Tumor
View Study & Checklist ➔Study of Sacituzumab Govitecan (SG) Versus Docetaxel in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
📍 Alaska Oncology and Hematology, LLC. — Anchorage, Alaska
Non-Small Cell Lung Cancer
View Study & Checklist ➔Comparing the New Anti-cancer Drug Eribulin With Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothelial Cancer
📍 Kingman Regional Medical Center — Kingman, Arizona
Metastatic Bladder Urothelial Carcinoma
View Study & Checklist ➔A Study of Sacituzumab Govitecan (IMMU-132) in Platinum-resistant Ovarian Cancer Patients
📍 Smilow Cancer Hospital at Yale New Haven — New Haven, Connecticut
Ovarian Carcinoma
View Study & Checklist ➔Testing Sacituzumab Govitecan Therapy in Patients With HER2-Negative Breast Cancer and Brain Metastases
📍 Anchorage Associates in Radiation Medicine — Anchorage, Alaska
Anatomic Stage IV Breast Cancer AJCC v8
View Study & Checklist ➔Sacituzumab Govitecan for the Treatment for Patients With Locally Advanced, Recurrent, or Metastatic Cholangiocarcinoma
📍 University of Kansas Cancer Center — Kansas City, Kansas
Locally Advanced Cholangiocarcinoma
View Study & Checklist ➔A Single-arm Phase II Trial of SAcituzumab Govitecan and Trastuzumab for HER2+ Metastatic Breast Cancer After Trastuzumab dEruxtEcaN (SATEEN)
📍 Miami Cancer Institute at Baptist Health — Miami, Florida
Her 2 Positive Breast Cancer
View Study & Checklist ➔A Phase II Study of Neoadjuvant Sacituzumab Govitecan and Pembrolizumab Therapy for Immunochemotherapy-resistant Early-stage Triple-negative Breast Cancer (TNBC)
📍 M D Anderson Cancer Center — Houston, Texas
Breast Cancer
View Study & Checklist ➔First-Line Sacituzumab Govitecan in Advanced Untreated Triple-Negative Breast Cancer Patients.
📍 BC Cancer - Vancouver Center — Vancouver, British Columbia
Advanced Triple Negative Breast Cancer
View Study & Checklist ➔Scalp Cooling in MBC
📍 Brigham and Women's Hospital — Boston, Massachusetts
Metastatic Breast Cancer
View Study & Checklist ➔Study of Sacituzumab Govitecan in Participants With Advanced or Metastatic Solid Tumor and Moderate Liver Impairment
📍 Pacific Shores Medical Group — Long Beach, California
Advanced or Metastatic Solid Tumor
View Study & Checklist ➔Sequential Therapies Modeled on Evolutionary Dynamics for Breast Cancer
📍 Moffitt Cancer Center — Tampa, Florida
Metastatic Breast Cancer
View Study & Checklist ➔Phase II Trial of Sacituzumab Govitecan in Recurrent and/or Metastatic Secretory Gland Cancers
📍 M D Anderson Cancer Center — Houston, Texas
Gland
View Study & Checklist ➔A Phase II Trial of Sacituzumab Govitecan in Patients With Advanced Thymic Epithelial Tumors
📍 Stanford Cancer Institute — Palo Alto, California
Thymoma
View Study & Checklist ➔Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)
📍 University of California San Francisco — San Francisco, California
Breast Cancer
View Study & Checklist ➔Liquid-biopsy Informed Platform Trial to Evaluate CDK4/6-inhibitor Resistant ER+/HER2- Metastatic Breast Cancer
📍 Arthur J.E. Child Comprehensive Cancer Centre — Calgary, Alberta
Breast Cancer
View Study & Checklist ➔A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan-hziy Versus Standard of Care in the Treatment of Advanced Urothelial Cancer
📍 Cancer Center at Saint Joseph's — Phoenix, Arizona
Locally Advanced Urothelial Carcinoma
View Study & Checklist ➔Saci Nivo Rela for TNBC
📍 Yale University — New Haven, Connecticut
Metastatic Triple-negative Breast Cancer
View Study & Checklist ➔Adjuvant Sacituzumab Govitecan and Nivolumab in Muscle-Invasive Urothelial Carcinoma at High-Risk Recurrence
📍 Chao Family Comprehensive Cancer Center, University of California, Irvine — Orange, California
Urothelial Carcinoma
View Study & Checklist ➔A Study of Sacituzumab Govitecan in People With Mesothelioma
📍 Memorial Sloan Kettering Basking Ridge — Basking Ridge, New Jersey
Mesothelioma
View Study & Checklist ➔A Study of Sacituzumab Govitecan (IMMU-132) in Patients With Recurrent or Persistent Cervical Cancer
📍 Smilow Cancer Hospital at Yale New Haven — New Haven, Connecticut
Cervical Cancer
View Study & Checklist ➔Genomic and Transcriptomic Predictors of Sequential SG Sensitivity After T-DXd in ER+/HER2-Low Metastatic Breast Cancer
📍 BC Cancer - Vancouver Center — Vancouver, British Columbia
Breast Cancer
View Study & Checklist ➔Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA LOW MBC
📍 Baptist Health Herbert Wertheim Cancer Institute — Miami, Florida
Breast Cancer
View Study & Checklist ➔Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC
📍 Stamford Hospital — Stamford, Connecticut
Breast Cancer
View Study & Checklist ➔A Study of Invikafusp Alfa (STAR0602), a Selective T Cell Receptor (TCR)-Targeting, Bifunctional Antibody-fusion Molecule, in Combination With Sacituzumab Govitecan in Participants With Advanced Solid Tumors
📍 USC Norris Comprehensive Cancer Center — Los Angeles, California
Triple Negative Locally Advanced Non-resectable Breast Cancer
View Study & Checklist ➔Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
📍 Alabama Oncology — Birmingham, Alabama
Triple Negative Breast Cancer
View Study & Checklist ➔A Study of Sacituzumab Govitecan in Combination With Cetuximab in People With Head and Neck Squamous Cell Cancer (HNSCC)
📍 Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities) — Basking Ridge, New Jersey
Squamous Cell Carcinoma of Head and Neck
View Study & Checklist ➔Sacituzumab Govitecan in Recurrent Glioblastoma
📍 Cleveland Clinic Taussig Cancer Center — Cleveland, Ohio
Recurrent Glioblastoma
View Study & Checklist ➔Sacituzumab Govitecan Plus EV in Metastatic UC
📍 Dana Farber Cancer Institute — Boston, Massachusetts
Urothelial Cancer
View Study & Checklist ➔Sacituzumab Govitecan and Zimberelimab w/SRS in the Management of Metastatic Triple Negative Breast Cancer With Brain Metastases
📍 Moffitt Cancer Center — Tampa, Florida
Breast Cancer
View Study & Checklist ➔Sacituzumab Govitecan With or Without Atezolizumab Immunotherapy in Rare Genitourinary Tumors (SMART) Such as High Grade Neuroendocrine Carcinomas, Adenocarcinoma, and Squamous Cell Bladder/Urinary Tract Cancer, Renal Medullary Carcinoma and Penile C...
📍 National Institutes of Health Clinical Center — Bethesda, Maryland
Small Cell Carcinoma of the Bladder
View Study & Checklist ➔Adaptive RADiation Therapy With Concurrent Sacituzumab Govitecan (SG) for Muscle Invasive Bladder Cancer
📍 Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center — Cleveland, Ohio
Localized Muscle Invasive Bladder Urothelial Carcinoma
View Study & Checklist ➔Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer
📍 Alaska Oncology and Hematology — Anchorage, Alaska
Extensive Stage Small Cell Lung Cancer (ES-SCLC)
View Study & Checklist ➔Study of Sacituzumab Govitecan With Atezolizumab/Durvalumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer
📍 Henry Ford Cancer- Detroit — Detroit, Michigan
Small Cell Lung Cancer ( SCLC )
View Study & Checklist ➔Study of AVZO-021 in Patients With Advanced Solid Tumors
📍 Yale Cancer Center — New Haven, Connecticut
Advanced Solid Tumor
View Study & Checklist ➔Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread
📍 The University of Arizona Cancer Center-North Campus — Tucson, Arizona
Metastatic Urothelial Cancer
View Study & Checklist ➔Study of Naxitamab and Sacituzumab Govitecan in Patients With Metastatic Triple-negative Breast Cancer (TNBC)
📍 The University of Texas M. D. Anderson Cancer Center — Houston, Texas
Metastatic Triple-Negative Breast Cancer
View Study & Checklist ➔Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer
📍 UC Irvine Health/Chao Family Comprehensive Cancer Center — Orange, California
Anatomic Stage IV Breast Cancer AJCC v8
View Study & Checklist ➔Study of GS-0201 Alone and in Combination in Participants With Advanced Solid Tumors
📍 Dana-Farber Cancer Institute — Boston, Massachusetts
Advanced Solid Tumors
View Study & Checklist ➔Sacituzumab Govitecan In TNBC
📍 Beth Israel Deaconess Medical Center — Boston, Massachusetts
Invasive Breast Cancer
View Study & Checklist ➔A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer
📍 City of Hope — Duarte, California
Metastatic Breast Cancer
View Study & Checklist ➔Circulating Tumor DNA to Guide Changes in Standard of Care Chemotherapy
📍 Vanderbilt University/Ingram Cancer Center — Nashville, Tennessee
Metastatic HER2-Negative Breast Carcinoma
View Study & Checklist ➔A Study of Sacituzumab Govitecan Given at an Alternative Dose and Schedule in Participants With Advanced Triple-Negative Breast Cancer
📍 Los Angeles Cancer Network (LACN) - Good Sam — Los Angeles, California
Triple Negative Breast Cancer
View Study & Checklist ➔Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial)
📍 City of Hope Comprehensive Cancer Center — Duarte, California
Advanced Malignant Solid Neoplasm
View Study & Checklist ➔